Immunic Historical Financial Ratios
| IMUX Stock | USD 1.13 0.08 6.61% |
Immunic is lately reporting on over 113 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 1.46 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Immunic financial condition quickly.
Immunic |
About Immunic Financial Ratios Analysis
ImmunicFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Immunic investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Immunic financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Immunic history.
Immunic Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Immunic stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Immunic sales, a figure that is much harder to manipulate than other Immunic multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Immunic dividend as a percentage of Immunic stock price. Immunic dividend yield is a measure of Immunic stock productivity, which can be interpreted as interest rate earned on an Immunic investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to Immunic. There are two different methods for calculating Immunic invested capital: operating approach and financing approach. Understanding Immunic invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Roic
Return on Invested Capital, a profitability ratio that measures the return that an investment generates for those who have provided capital, such as debt holders and equity holders.Most ratios from Immunic's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.At this time, Immunic's Book Value Per Share is fairly stable compared to the past year. Capex To Depreciation is likely to rise to 3.16 in 2024, whereas PTB Ratio is likely to drop 1.46 in 2024.
| 2010 | 2023 | 2024 (projected) | Dividend Yield | 0.007985 | 0.007187 | 0.006388 | Price To Sales Ratio | 21.6K | 19.5K | 17.3K |
Immunic fundamentals Correlations
Click cells to compare fundamentals
Immunic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunic fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 1.28 | 1.51 | 1.78 | 0.39 | 2.3 | 1.46 | |
| Book Value Per Share | 7.56 | 10.14 | 5.37 | 3.57 | 0.65 | 0.69 | |
| Free Cash Flow Yield | (0.38) | (0.19) | (0.37) | (1.46) | (1.07) | (1.12) | |
| Operating Cash Flow Per Share | (3.7) | (2.94) | (3.52) | (2.05) | (1.6) | (1.68) | |
| Capex To Depreciation | 1.1 | 3.74 | 0.79 | 1.45 | 3.01 | 3.16 | |
| Pb Ratio | 1.28 | 1.51 | 1.78 | 0.39 | 2.3 | 1.46 | |
| Free Cash Flow Per Share | (3.7) | (2.95) | (3.52) | (2.05) | (1.61) | (1.69) | |
| Roic | (3.43) | (0.63) | (0.31) | (0.72) | (1.35) | (3.26) | |
| Inventory Turnover | (0.12) | 0.0114 | (0.0395) | (0.029) | (0.0261) | (0.0274) | |
| Net Income Per Share | (4.51) | (2.81) | (3.92) | (4.85) | (2.11) | (2.22) | |
| Days Of Inventory On Hand | (3.0K) | 32.0K | (9.2K) | (12.6K) | (14.5K) | (13.8K) | |
| Payables Turnover | 0.0206 | 0.0105 | 0.0227 | 0.018 | 0.0218 | 0.0207 | |
| Cash Per Share | 3.8 | 8.14 | 3.67 | 3.66 | 1.05 | 1.0 | |
| Pocfratio | (2.62) | (5.19) | (2.72) | (0.68) | (0.94) | (0.99) | |
| Capex To Operating Cash Flow | (0.001927) | (0.003165) | (8.05E-4) | (0.001719) | (0.004716) | (0.004951) | |
| Pfcf Ratio | (2.62) | (5.18) | (2.72) | (0.68) | (0.93) | (0.98) | |
| Days Payables Outstanding | 17.7K | 34.6K | 16.1K | 20.3K | 16.8K | 10.0K | |
| Income Quality | 0.82 | 1.05 | 0.9 | 0.54 | 0.76 | 1.02 | |
| Roe | (0.6) | (0.28) | (0.73) | (1.36) | (3.24) | (3.07) | |
| Ev To Operating Cash Flow | (1.61) | (2.44) | (1.68) | 0.93 | (0.3) | (0.31) | |
| Pe Ratio | (2.15) | (5.45) | (2.44) | (0.29) | (0.71) | (0.75) | |
| Ev To Free Cash Flow | (1.61) | (2.44) | (1.68) | 0.93 | (0.3) | (0.31) | |
| Net Debt To E B I T D A | 0.78 | 2.59 | 0.93 | 0.87 | 0.46 | 0.43 | |
| Current Ratio | 4.56 | 15.93 | 9.21 | 9.62 | 2.12 | 2.02 | |
| Tangible Book Value Per Share | 3.29 | 8.03 | 3.98 | 3.57 | 0.65 | 0.69 | |
| Graham Number | 27.69 | 25.3 | 21.78 | 19.74 | 5.57 | 5.29 | |
| Shareholders Equity Per Share | 7.56 | 10.14 | 5.37 | 3.57 | 0.65 | 0.69 | |
| Capex Per Share | 0.007122 | 0.009321 | 0.002833 | 0.00352 | 0.007536 | 0.007159 | |
| Graham Net Net | 2.79 | 7.67 | 3.12 | 3.17 | 0.48 | 0.5 | |
| Enterprise Value Over E B I T D A | (1.25) | (2.3) | (1.51) | 0.5 | (0.21) | (0.22) | |
| Price Earnings Ratio | (2.15) | (5.45) | (2.44) | (0.29) | (0.71) | (0.75) | |
| Price Book Value Ratio | 1.28 | 1.51 | 1.78 | 0.39 | 2.3 | 1.46 | |
| Price Earnings To Growth Ratio | 0.0243 | 0.14 | (0.0618) | (0.0122) | 0.0126 | 0.0132 | |
| Days Of Payables Outstanding | 17.7K | 34.6K | 16.1K | 20.3K | 16.8K | 10.0K | |
| Price To Operating Cash Flows Ratio | (2.62) | (5.19) | (2.72) | (0.68) | (0.94) | (0.99) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.